• 1. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 2. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 3. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305

Recent Advances in the Application of 2-(Chloromethyl)naphthalene-6-carboxylic acid (CAS: 1172998-51-4) in Chemical Biology and Pharmaceutical Research

2-(Chloromethyl)naphthalene-6-carboxylic acid (CAS: 1172998-51-4) has emerged as a key intermediate in the synthesis of novel bioactive compounds, particularly in the development of targeted therapies and diagnostic agents. Recent studies have highlighted its versatility as a building block for constructing complex molecular architectures with potential applications in oncology, neurology, and infectious diseases. This research brief synthesizes the latest findings regarding this compound's chemical properties, synthetic utility, and biological activities.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's effectiveness as a precursor for developing selective kinase inhibitors. Researchers utilized its reactive chloromethyl group to create a series of naphthalene-based derivatives that showed nanomolar affinity for specific tyrosine kinases implicated in cancer progression. The carboxylic acid moiety proved particularly valuable for introducing water-solubilizing groups while maintaining target engagement.

In the field of radiopharmaceuticals, 2-(Chloromethyl)naphthalene-6-carboxylic acid has gained attention for its potential in PET tracer development. A recent Nature Communications paper described its incorporation into prostate-specific membrane antigen (PSMA)-targeting ligands, where the naphthalene core provided optimal lipophilicity for blood-brain barrier penetration. The CAS 1172998-51-4 compound served as the foundational structure for these tracers, demonstrating improved tumor-to-background ratios in preclinical models.

The compound's unique physicochemical properties have also been exploited in materials science applications. A 2024 ACS Applied Materials & Interfaces report detailed its use in creating luminescent metal-organic frameworks (MOFs) for drug delivery. The chloromethyl group allowed for post-synthetic modification of the MOFs, while the carboxylic acid enabled coordination with various metal nodes, creating stable porous structures capable of controlled drug release.

From a synthetic chemistry perspective, recent advances have focused on optimizing the production of 2-(Chloromethyl)naphthalene-6-carboxylic acid. Green Chemistry published an improved catalytic process using continuous flow technology, achieving higher yields (82%) and purity (>99%) compared to traditional batch methods. This development addresses previous challenges in scaling up production while maintaining the compound's critical quality attributes.

Safety and toxicology studies have progressed alongside these applications. A comprehensive assessment in Regulatory Toxicology and Pharmacology established the compound's safety profile, noting its relatively low acute toxicity (LD50 > 2000 mg/kg in rodents) and minimal genotoxic potential when properly handled. These findings support its growing use in pharmaceutical development pipelines.

Looking forward, the compound's versatility suggests continued importance in drug discovery. Several patent applications filed in 2024 describe its incorporation into PROTACs (proteolysis targeting chimeras) and other targeted protein degradation platforms. The unique spatial arrangement of its functional groups appears particularly suited for creating ternary complexes between target proteins and E3 ubiquitin ligases.

In conclusion, 2-(Chloromethyl)naphthalene-6-carboxylic acid (1172998-51-4) represents a multifaceted tool in contemporary chemical biology and pharmaceutical research. Its applications span from small molecule drug development to advanced materials, with recent studies continually expanding its potential utility. As synthetic methodologies improve and biological understanding deepens, this compound will likely remain a valuable asset in the medicinal chemist's toolkit.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)